MethMMaibachJ: Howard I Current understanding of contrast media reactions and implications for clinical management. Drug Safety29 (2): 133–141, 2006.
2.
MorteléKJOlivaMROndateguiS: Universal use of nonionic iodinated contrast medium for CT: Evaluation of safety in a large urban teaching hospital. American Journal of Roentgenology184: 31–34, 2005.
3.
BrockowKChristiansenCKannyG: ENDA*, the EAACI interest group on drug hypersensitivity management of hypersensitivity reactions to iodinated contrast media. Allergy60: 150–158, 2005.
4.
KatayamaHYamaguchiKKozukaT: Adverse reactions to ionic and non-ionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology175: 621–28, 1990.
5.
DillmanJREllisJHCohanRH: Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. American Journal of Roentgenology189: 1533–1538, 2007.
6.
GreenbergerPAPattersonR: The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol87: 867–872, 1991.
7.
MorcosSKThomsenHSWebbJA: Prevention of generalized reactions to contrast media: A consensus report and guidelines. Eur Radiol11: 1720–1728, 2001.
8.
American College of Radiology: Manual on contrast media, 5th ed.Reston, VA: American College of Radiology, 2004.
9.
DillmanJREllisJHCohanRH: Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. American Journal of Roentgenology190: 187–190, 2008.
10.
LasserECBerryCCTalnerLB: Pre-treatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med317: 845–9, 1987.
11.
BeckerC: Prophylaxis and treatment of side effects due to iodinated contrast media relevant to radiological practice. Radiologe47 (9): 768–73, 2007.
12.
LasserCEBerryCCMishkinMM: Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. American Journal of Roentgenology162: 523–26, 1994.
13.
TramèrMRvon ElmELoubeyreP: Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: Systematic review. BMJ333: 675, 2006.
14.
CarchiettiE: Reazioni averse da mezzi di contrasto in Neuroradiologia. Profilassi e terapia. Rivista di Neuroradiologia5: 119–124, 1992.
15.
LagunoffDMartinTWReadG: Agents that release histamine from mastcells. Ann Rev Pharmacol Toxicol23: 331–351, 1983.
16.
ValfreyJNewingerGArbogastR: Choc à l'ioxaglate (Hexabrix 320®) lors de coronarographies. À propos de deux cas: Anaphylactic shock with ioxaglate during coronary angiography: Two cases. Rev Fr Allergol Immunol Clin42: 157–162, 2002.
17.
MorcosSK: Acute serious and fatal reactions to contrast media: Our current understanding. Br J Radiol78: 686–693, 2005.
LarocheDAimone-GastinIDuboisF: Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology209: 183–190, 1998.
20.
SchwartzLBBradfordTRRouseC: Development of a new more sensitive immunoassay for human tryptase use in systematic anaphylaxis. J Clin Immunol14 (3): 190–204, 1994.
21.
HoganDuff ASchwartzL: Markers of mast cell degranulation. Methods13: 43–52, 1997.
22.
BartlettMJByneveltM: Acute contrast reaction management by radiologists: A local audit study. Australasian Radiol47 (4): 363–367, 2003.
23.
BarrancoPLopez-SerranoMC: General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy28 (suppl 4): 61–2, 1998.
24.
BayardPJBergerTGJacobsonMA: Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr5: 1237–57, 1992.
25.
DescampsVValanceAEdlingerC: Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol137: 301–4, 2001.
26.
LangDMAlpernMBVisintainerPF: Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med115: 270–6, 1991.
27.
AdkinsonNFJr: Risk factors for drug allergy. J Allergy Clin Immunol74: 567–72, 1984.
28.
PedersenPAWeekeER: Asthma and allergic rhinitis in the same patients. Allergy38: 25–29, 1983.
29.
BarnesPJItoKAdcockIM: A mechanism of corticosteroid resistance in COPD: Inactivation of histone deacetylase. Lancet363: 731–733, 2004.
30.
BarnesPJ: Theophylline: New perspectives on an old drug. Am J Respir Crit Care Med167: 813–818, 2003.
31.
BarnesPJ: Theophylline in chronic obstructive pulmonary disease: New horizons. Proc Am Thorac Soc2: 334–339, 2005.
32.
CosioBGTsaprouniLItoK: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med200: 689–695, 2004.
33.
VernassiereCTrechotPSchmutzJL: Results and negative value of skin tests in investigating delayed reactions to radiocontrast media, Allergologie27: 164–167, 2004.
34.
LarocheD: Immediate reactions to contrast media: Mediator release and value of diagnostic testing. Toxicology2009 (2): 193–194, 2005.
35.
BrockowKChristiansenCKannyG: ENDA*, the EAACI interest group on drug hypersensitivity management of hypersensitivity reactions to iodinated contrast media. Allergy60: 150–158, 2005.
36.
SimonGABrownMBBS: Clinical features and severity grading of anaphylaxis. Journal of Allergy and Clinical Immunology114: 371–376, 2004.
37.
LiebermanP: The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol86: 684–686, 1990.
38.
FeltrinGPZandonàMBorileV: Fondamenti sui mezzi di contrasto iodati e reazioni avverse. Radiol Med107: 8–31, 2004.
39.
JutelMWatanabeTAkdisM: Immune regulation by histamine. Current Opinion In Immunology14: 735–40, 2002.
40.
GaleotalanzaCMagliacaneDPadaroG: Ruolo dei recettori istaminergici nella regolazione della risposta immune. Giorn It Allergol Immunol Clin14: 153–164, 2004.
BakkerRAWielandKTimmermanH: Constitutive activity of the histamine H1-receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur J Pharmacol387: R5–R7, 2000.
43.
AHFS Drug Information 2007.
44.
BambergerCMBambergerAMde CastrM: Glucocorticoid receptor b, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest95: 2435–2441, 1995.
45.
ButtgereitFBrandMDBurmesterGR: Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: A novel glucocorticoid hierarchy. Biochem Pharmacol58: 363–368, 1999.
46.
SongIHGoldRStraubRH: New glucocorticoids on the horizon: Repress, dont activate! J. Rheumatol32: 1199–1207, 2005.
WehlingM: Specific Nongenomic actions of steroid hormones. Annu Rev Physiol59: 365–93, 1997.
49.
LipworthBJ: Therapeutic implications of non-genomic glucocorticoid activity. Lancet356: 87–9, 2000.
50.
HardmanJGLimbirdLEGilmanAG: Le basi farmacologiche della terapia. Edizione italiana a cura di: SirtoriC.CelottiF.FolcoG.FranceschiniG.CovoniS.McGraw-Hill Companies. Milano.
51.
RhenTCidlowskiJA: Antiinflammatory action of glucocorticoids. New mechanisms for old drugs. N Engl J Med353: 1711–23, 2005.
52.
PujolsLMullolJPérezM: Expression of the human glucocorticoid receptor α and β isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol24: 49–57, 2001.
53.
ButtgereitFDa SilvaJAPBoersM: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann Rheum Dis61: 718–722, 2002.
54.
ButtgereitFBrandNDMullerM: Effects of methylprednisolone on the energy metabolism of quiescent and concanavalin-A stimulated thymocytes of the rat. Biosci Rep13: 41–52, 1993.
55.
LipworthBJ: Therapeutic implications of non-genomic glucocorticoid activity. Lancet356: 87–9, 2000.
56.
SchmidtBMGerdesDFeuringM: Rapid. Non-genomic steroid actions: A new age?Front Neuroendocrinol21: 57–94, 2000.
57.
RhenTCidlowskiJA: Antiinflammatory action of glucocorticoids. New mechanisms for old drugs. N Engl J Med353: 1711–23, 2005.
